125 related articles for article (PubMed ID: 34399207)
41. Delivered dose uncertainty analysis at the tumor apex for ocular brachytherapy.
Morrison H; Menon G; Larocque MP; Jans HS; Weis E; Sloboda RS
Med Phys; 2016 Aug; 43(8):4891. PubMed ID: 27487906
[TBL] [Abstract][Full Text] [Related]
42. Comparison of 16 mm OSU-Nag and COMS eye plaques.
Zhang H; Davidorf F; Qi Y
J Appl Clin Med Phys; 2012 May; 13(3):3632. PubMed ID: 22584165
[TBL] [Abstract][Full Text] [Related]
43. Technical Note: Monte Carlo study of
Hermida-López M; Brualla L
Med Phys; 2017 Jun; 44(6):2581-2585. PubMed ID: 28370303
[TBL] [Abstract][Full Text] [Related]
44. Monte Carlo Estimation of Absorbed Dose Distributions Obtained from Heterogeneous
Zaragoza FJ; Eichmann M; Flühs D; Sauerwein W; Brualla L
Ocul Oncol Pathol; 2017 Sep; 3(3):204-209. PubMed ID: 29071271
[TBL] [Abstract][Full Text] [Related]
45. EGSnrc-based Monte Carlo dosimetry of CSA1 and CSA2 137Cs brachytherapy source models.
Selvam TP; Sahoo S; Vishwakarma RS
Med Phys; 2009 Sep; 36(9):3870-9. PubMed ID: 19810459
[TBL] [Abstract][Full Text] [Related]
46. Comparison between dose distribution from
Taherparvar P; Fardi Z
Appl Radiat Isot; 2022 Apr; 182():110146. PubMed ID: 35182934
[TBL] [Abstract][Full Text] [Related]
47. Calculation of dose distributions for 12 106Ru/106Rh ophthalmic applicator models with the PENELOPE Monte Carlo code.
Hermida-López M
Med Phys; 2013 Oct; 40(10):101705. PubMed ID: 24089895
[TBL] [Abstract][Full Text] [Related]
48. Delivered dose changes in COMS plaque-based ocular brachytherapy arising from vitrectomy with silicone oil replacement.
Morrison H; Larocque MP; Menon G; Sloboda RS; Weis E
Brachytherapy; 2019; 18(5):668-674. PubMed ID: 31272841
[TBL] [Abstract][Full Text] [Related]
49. Monte Carlo Simulation of the Treatment of Uveal Melanoma Using Measured Heterogeneous
Zaragoza FJ; Eichmann M; Flühs D; Wittig A; Sauerwein W; Brualla L
Ocul Oncol Pathol; 2019 Jun; 5(4):276-283. PubMed ID: 31367591
[TBL] [Abstract][Full Text] [Related]
50. Method for verifying the air kerma strength of I-125 plaques for the treatment of ocular melanoma.
Zimmermann LW; Wilkinson DA
J Appl Clin Med Phys; 2014 Jul; 15(4):4880. PubMed ID: 25207419
[TBL] [Abstract][Full Text] [Related]
51. On the use of the absorbed depth-dose measurements in the beam calibration of a surface electronic high-dose-rate brachytherapy unit, a Monte Carlo-based study.
Valdes-Cortez C; Niatsetski Y; Ballester F; Vijande J; Candela-Juan C; Perez-Calatayud J
Med Phys; 2020 Feb; 47(2):693-702. PubMed ID: 31722113
[TBL] [Abstract][Full Text] [Related]
52. Radiobiology for eye plaque brachytherapy and evaluation of implant duration and radionuclide choice using an objective function.
Gagne NL; Leonard KL; Rivard MJ
Med Phys; 2012 Jun; 39(6):3332-42. PubMed ID: 22755715
[TBL] [Abstract][Full Text] [Related]
53. Intensity modulated high dose rate ocular brachytherapy using Se-75.
Dupere JM; Munro JJ; Medich DC
Brachytherapy; 2021; 20(6):1312-1322. PubMed ID: 34561174
[TBL] [Abstract][Full Text] [Related]
54. A novel quality assurance system for eye plaque brachytherapy.
Kejda A; Cutajar D; Weaver M; Petasecca M; Rosenfeld A
Australas Phys Eng Sci Med; 2019 Dec; 42(4):1109-1115. PubMed ID: 31728937
[TBL] [Abstract][Full Text] [Related]
55. Dosimetric validation of the Theragenics AgX-100® I-125 seed for ROPES eye plaque brachytherapy.
Pagulayan C; Heng SM; Corde S
Australas Phys Eng Sci Med; 2019 Jun; 42(2):599-609. PubMed ID: 31087233
[TBL] [Abstract][Full Text] [Related]
56. BEDVH-A method for evaluating biologically effective dose volume histograms: application to eye plaque brachytherapy implants.
Gagne NL; Leonard KL; Huber KE; Mignano JE; Duker JS; Laver NV; Rivard MJ
Med Phys; 2012 Feb; 39(2):976-83. PubMed ID: 22320806
[TBL] [Abstract][Full Text] [Related]
57. COMS eye plaque brachytherapy dosimetry simulations for 103Pd, 125I, and 131Cs.
Melhus CS; Rivard MJ
Med Phys; 2008 Jul; 35(7):3364-71. PubMed ID: 18697560
[TBL] [Abstract][Full Text] [Related]
58. egs_brachy: a versatile and fast Monte Carlo code for brachytherapy.
Chamberland MJ; Taylor RE; Rogers DW; Thomson RM
Phys Med Biol; 2016 Dec; 61(23):8214-8231. PubMed ID: 27804922
[TBL] [Abstract][Full Text] [Related]
59. Optic disc dose reduction in ocular brachytherapy using
Lee YC; Lin SC; Kim Y
J Appl Clin Med Phys; 2020 Sep; 21(9):57-70. PubMed ID: 32656945
[TBL] [Abstract][Full Text] [Related]
60. Investigating the dosimetric impact of seed location uncertainties in Collaborative Ocular Melanoma Study-based eye plaques.
Johnson JE; Deufel CL; Furutani KM
Brachytherapy; 2016; 15(5):661-8. PubMed ID: 27475484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
